UNSPSC 51111857: Lasofoxifene

This classification denotes a selective estrogen receptor modulator with the molecular formula C28H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 337G83N988, chemically known as 2-naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, (5r-cis)- but generally known as lasofoxifene, which bears US NIH Compound Identifier 216416. European Medicines Agency schedules Lasofoxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27754.

UNSPSC 51111857 Lasofoxifene, a Commodity code, covers osteoporosis and bone-health pharmaceutical products that state and local government entities procure through cooperative purchasing vehicles and multistate pharmaceutical procurement frameworks. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and similar state-level purchasing consortia are the primary issuing bodies under this code, aggregating demand across participating state agencies, local health departments, correctional facilities, and other public-health entities to negotiate volume pricing with manufacturers and establish long-term supply agreements.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The RFP requires manufacturers to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain contractual relationships with at least two of the three wholesalers with chargeback systems in place, and submit detailed product information including National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, trade names, and manufacturing locations. Evaluation is weighted 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 5 percent each on administrative-fee-format compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term is two years for new responders with optional extensions, or alignment with existing agreement expiration dates through June 30, 2028, for incumbent responders. All products must be available in the marketplace by May 15, 2026, when awarded vendors will be provided to wholesalers and resulting agreements become effective July 1, 2026. Minnesota and Oregon are the named participating jurisdictions in the available documentation.